Aligning with this hypothesis, several GLP-1R agonists have shown neuroprotective efficacy against AD and Parkinson’s disease (PD) pathology, reducing microgliosis and astrogliosis (Aviles-Olmos et al., 2013; Athauda et al., 2017; Park et al., 2021). The gene discussed is GLP1R; the disease is Alzheimer disease.